An inherent T cell-activating mRNA delivery carrier for in vivo CAR T generation.

Qiannan Cao Yingli Yao Wenming Zheng Hong-Qian Liu Mingxia Jiang Dayang Xie Siting Zhang Pijun Su Hui-Lin Yuan Xiao-Yuan Chen Huapan Fang Huayu Tian

Aug 2026 · Nature Materials · 3 citations · 69 references

Medicine

TL;DR

An inherent T cell-activating polymer-lipid nanoparticle that enables ligand-free, efficient mRNA transfection and activation of T cells in vivo, and provides a clinically translatable approach for in vivo CAR T cell generation.

DOI PubMed Semantic Scholar

View source

Similar papers

Aug 2026

In Situ Generation of Claudin18.2-Specific CAR-T Cells via Lipid Nanoparticle-Mediated mRNA Delivery.

Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable clinical success in hematological malignancies; however, its broader application is limited by high manufacturing costs and insufficient efficacy against solid tumors. To overcome these challenges, an in situ CAR-T cell generation strategy was devel...

He Li, Jing-Yun Li, Ying Wang et al. · Journal of Visualized Experi... · 0 citations

Review Open access Sep 2026

In vivo CAR T-cell generation: delivery platforms, clinical progress, and translational barriers

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of several hematological malignancies, but its broader application remains constrained by the complexity, cost, and time required for conventional ex vivo manufacturing. In vivo CAR T-cell therapy has emerged as a promising next-generation str...

Tian-Qun Huo, Hong-Ping Yao, Zi-Yan Kong · Frontiers in Immunology · 0 citations

Aug 2026

Polyaspartamide-Mediated Messenger RNA Delivery Enables Efficient Ex Vivo Engineering of Chimeric Antigen Receptor Natural Killer Cells via Enhanced Cellular Internalization.

Engineered natural killer (NK) cells expressing chimeric antigen receptor (CAR) represent a promising alternative to CAR T-cell therapy due to their allogeneic potential. However, current CAR NK cell production relies on lentiviral or retroviral transduction to achieve stable CAR expression, requiring complex, multiste...

Ha Yeon Park, Seon-Jeong Kim, Kyuree Kim et al. · ACS Applied Materials and In... · 0 citations

#gene editing Review Open access Sep 2026

Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy

Cancer immunotherapy is a transformative technology allowing for the elimination of malignant cells through immune system stimulation; however, the large-scale clinical application of adoptive cellular therapy technologies is limited due to difficulties in ex vivo immune cell engineering, high costs, and complicated ma...

Hari Krishnareddy Rachamala, Sandeep Atla, R. S. Angom · Frontiers in Pharmacology · 0 citations

#gene editing Open access Sep 2026

Click-Chemistry Functionalized Lipid Nanoparticles for In Vitro and In Vivo Transfection of Primary Human CD4+ T Cells.

CD4+ T cells orchestrate adaptive immunity and strategies that enable their genetic reprogramming hold promise for treating cancer, immune dysregulation and infectious diseases such as HIV. However, current T cell engineering approaches rely heavily on ex vivo manipulation, which is labor-intensive, costly, and can alt...

Maaike De Cock, Elianne Burg, Sarah Gerlo et al. · Advanced Healthcare Material... · 0 citations

Open access Sep 2026

Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles

Human T cells modified with nucleic acids constitute a powerful and emerging therapeutic modality for cancer, autoimmune disorders, and aging-related diseases. However, delivering nucleic acids, such as mRNA encoding synthetic receptors, transcription factors, cytokines, or genome editors to T cells can be challenging,...

Apoorva Ramamurthy, Giulia Scimonelli, William L. Murphy et al. · Molecular Therapy: Nucleic A... · 0 citations